A Study of Sotorasib in People With Brain Tumors
Part of paid clinical trials in Basking Ridge, New Jersey.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT06807619
- Phase
- PHASE1
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Sotorasib — DRUGEnrolled patients will be administered DCOI at the FDA-recommended dose or continued on the DCOI at the discretion of the treating Oncologist per standard of care
Study Details
The researchers are doing this study to find out how effective sotorasib is at getting into KRAS G12C+ brain tumors. The researchers will also find out whether sotorasib is a safe and effective treatment for people undergoing surgical resection of KRAS G12C+ metastatic brain tumors, and do tests that show how the body absorbs, distributes, and gets rid of sotorasib.
Key Dates
- Start date
- Jan 29, 2025
- Status verified
- May 2026
- Primary completion
- Jan 31, 2028
- Completion
- Jan 31, 2028
Study Design
- Enrollment
- 16 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: DCOI naïveWill receive the standard dose of sotorasib.
- Active Comparator: Progressed on the DCOIWill continue to receive the sotorasib dose they were previously receiving, according to their doctor's instruction.
Primary Outcome Measure
ORR (overall response rate) [ Time Frame: 1 year ]
Central Contacts
- Nelson Moss, MD212-639-7075
- Cameron Brennan, MD212-639-8268
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | 07920 | Nelson Moss, MD 212-639-7075 |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | New Jersey | 07748 | Nelson Moss, MD 212-639-7075 |
| Memorial Sloan Kettering Commack (Limited Protocol Activities) | Commack | New York | 11725 | Nelson Moss, MD 212-639-7075 |
| Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) | Commack | New York | 11725 | Nelson Moss, MD 212-639-7075 |
| Memorial Sloan Kettering West Harrison (Limited Protocol Activities) | Harrison | New York | 10604 | Nelson Moss, MD 212-639-7075 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | New York | 10065 | Nelson Moss, MD 212-639-7075 |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale | New York | 11553 | Nelson Moss, MD 212-639-7075 |
Find similar trials in Basking Ridge, NJ
By condition
By specialty
By research site
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Commack (Limited Protocol Activities)· Commack, NYMemorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)· Commack, NYMemorial Sloan Kettering West Harrison (Limited Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY
Related Studies
- Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOAPHASE2 · Recruiting · Northwell Health · New York, New York
- Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed GlioblastomaPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York
- Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBMPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York
- Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental DisordersRecruiting · Southwest Autism Research & Resource Center · Phoenix, Arizona